The Global Multiple Sclerosis Market 2009-2024

Table of Contents

1 Executive Summary

• 1.1 Multiple Sclerosis Market Review
• 1.2 Aims, Scope and Format of the Report

2 Introduction to Multiple Sclerosis

• 2.1 The Biology of MS
• 2.2 The Disease
  • 2.2.1 Symptoms of MS
  • 2.2.2 Diagnosis of MS
• 2.3 Measuring MS
  • 2.3.1 The Kurtzke Expanded Disability Status Scale (EDSS)
• 2.4 The Different Types of MS
  • 2.4.1 Relapsing-Remitting MS
  • 2.4.2 Secondary Progressive MS
  • 2.4.3 Progressive Relapsing MS
  • 2.4.4 Primary Progressive MS
  • 2.4.5 Other Atypical Presentations
• 2.5 Causational Factors of MS
  • 2.5.1 Genetic Factors
  • 2.5.2 Infection
  • 2.5.3 Environmental Factors and Less Supported Theories
• 2.6 World Demographics and Economic Costs of MS
• 2.7 Treatment Options
  • 2.7.1 Alternative Treatments
  • 2.7.2 Medical Approaches
• 2.8 Pharmacotherapy
  • 2.8.1 Treatment of Acute Symptomatic Attack
  • 2.8.2 Disease-Modifying Treatments

3 The Market for MS Drugs 2009-2024

• 3.1 MS Market Analysis
• 3.2 The Leading MS Drugs - Overall Sales Comparisons
• 3.3 Biogen' s Avonex was Top-Selling MS Drug - How will it Fare?
  • 3.3.1 Avonex Sales from 2009 to 2024
  • 3.3.2 Patent Expiry in Major Markets Will Impact on Revenues
  • 3.3.3 How Will Increased Competition Affect Sales from 2010 Onwards?
• 3.4 Will Copaxone' s Revenues Increase Despite Competitive Threats?
  • 3.4.1 Copaxone and Direct Competition
  • 3.4.2 Will Product Development Increase Market Potential?
  • 3.4.3 Competition Resulting from Newer Therapies and Patent Expiry - What Effects on Sales?
• 3.5 Will Rebif' s Efficacy and Drug Delivery Lead to Market Dominance?
  • 3.5.1 Will Novel Delivery Mechanism Drive Sales in the Retail Sector?
  • 3.5.2 Rebif' s Sales During Forecast Period
• 3.6 Betaferon Faces Patent Expiry During the Forecast Period
  • 3.6.1 Will Betaferon Be Competitive Enough in the Market?
• 3.7 Will Re-Launched Tysabri Generate Blockbuster Sales?
  • 3.7.1 Two New PML Cases May Erode Sales
  • 3.7.2 Tysabri (natalizumab) for Oncology
• 3.8 Prospects for the Oral MS Drug Market
• 3.9 MS Market Summary 2009-2024

4 The Market for MS Drugs in the Seven Major Markets, 2009-2024

• 4.1 MS Drugs in the Seven Major Markets: Analysis
• 4.2 MS Market in the US
  • 4.2.1 Leading MS Products in the US Market
  • 4.2.2 Market Drivers
  • 4.2.3 Market Restraints
• 4.3 MS Market in Germany
  • 4.3.1 Leading MS Products in the German Market
  • 4.3.2 Market Drivers
  • 4.3.3 Market Restraints
• 4.4 MS Market in France
  • 4.4.1 Leading MS Products in the French Market
  • 4.4.2 Market Drivers
  • 4.4.3 Market Restraints
• 4.5 MS Market in Italy
  • 4.5.1 Leading MS Products in the Italian Market
  • 4.5.2 Market Drivers
  • 4.5.3 Market Restraints
• 4.6 MS Market in Canada
  • 4.6.1 Leading MS Products in the Canadian Market
  • 4.6.2 Market Drivers
  • 4.6.3 Market Restraints
• 4.7 MS Market in Spain
  • 4.7.1 Leading MS Products in the Spanish Market
  • 4.7.2 Market Drivers
  • 4.7.3 Market Restraints
• 4.8 MS Market in the UK
  • 4.8.1 Leading MS Products in the UK Market
  • 4.8.2 Market Drivers
  • 4.8.3 Market Restraints

5 An Analysis of Factors that Influence the Global MS Market

• 5.1 SWOT Analysis of the MS Market 2009-2024
• 5.2 Market Drivers
• 5.3 Market Restraints
• 5.4 The MS Market Has Opportunities for Continuing Growth
• 5.5 Entry of Oral MS Drugs Will Provide More-Accessible Treatment Options
• 5.6 Advances in Technology Likely to Bring Benefits to the Market
• 5.7 Comparative Studies - a Two-Edged Sword
• 5.8 Important Patient Sub-Populations: Potential for Companies to Increase Market Leverage Through Product Differentiation
• 5.9 Concerns Over the High Price of Treatments - Who Yields the Power?
• 5.10 A Discussion of Generic Drugs in This Market - How Great is Their Threat?
• 5.11 How Much Scope is There to Improve Safety and Tolerability in MS Drugs?

6 Leading Companies in MS Therapy Development

• 6.1 Key Companies Delivering MS Therapies Highlighted
  • 6.1.1 Biogen Idec and Elan Pharmaceuticals
  • 6.1.2 Merck Serono
  • 6.1.3 Bayer-Schering
  • 6.1.4 Sanofi-Aventis and Teva

7 Pipeline Drugs for MS

• 7.1 MS Pipeline Drugs
• 7.2 The Potential Treatment Options in MS
  • 7.2.1 Reducing Inflammatory Response
  • 7.2.2 Managing Autoimmune Response
  • 7.2.3 Manipulating the Permeability of the Blood-Brain Barrier
  • 7.2.4 Inhibiting Demyelination
  • 7.2.5 Protection Axons from Damage
  • 7.2.6 Encouraging Remyelination
• 7.3 Drugs that Regulate Immune Response by Destroying Lymphocytes
  • 7.3.1 Fingolimod (FTY720)
  • 7.3.2 Mylinax (Oral Formulation)
  • 7.3.3 Alemtuzumab
  • 7.3.4 Rituximab
• 7.4 Drugs that Manage Immune Activity
  • 7.4.1 Teriflunomide
  • 7.4.2 Laquinimod
  • 7.4.3 Daclizumab
  • 7.4.4 MBP 8298
  • 7.4.5 Integrin Inhibitors
• 7.5 Drugs that Reduce Inflammation
  • 7.5.1 BG-12
  • 7.5.2 MLN 1202
  • 7.5.3 Ibudilast
• 7.6 MS Vaccines
  • 7.6.1 Tovaxin
  • 7.6.2 BHT-3009
• 7.7 Drugs to Improve Nerve Function
  • 7.7.1 Fampridine-SR
  • 7.7.2 Lamotrigine
• 7.8 Pfizer' s Lipitor (atorvastin) and Other Statins
• 7.9 GW Sativex Investigational Cannabis-Based Treatment for MS 7.10 An "Oral Drug Revolution" in MS Treatment - a Possibility?
• 7.11 MS Pipeline Shows Short- and Long-Term Potential
• 7.12 The Future of MS Treatments
  • 7.12.1 Stem Cell Therapy
  • 7.12.2 Thyroid Hormone has Treatment Potential

8 Experts' Views

• 8.1 Interview with Dr. Rosie Jones from Bristol General Hospital, MS Research Unit, UK
  • 8.1.1 Introduction
  • 8.1.2 Understanding MS
  • 8.1.3 On Disease-Modifying Treatments
  • 8.1.4 On Oral Drugs
  • 8.1.5 On the Problems of Long-Term Treatments
  • 8.1.6 On Natalizumab (Tysabri) and Progressive Multifocal Leukoencephalopathy (PML)
  • 8.1.7 On Alternative Treatments
  • 8.1.8 On Medical Marijuana Use
  • 8.1.9 The Future of MS Treatments
• 8.2 Interview with Dr Johan Luthman (Merck Serono)
  • 8.2.1 On Understanding the Disease and its Treatment
  • 8.2.2 On Unmet Needs for MS Therapy
  • 8.2.3 On Current Treatment Options
  • 8.2.4 On Medical Marijuana Use
  • 8.2.5 On Oral Drugs
  • 8.2.6 On Future Treatment Possibilities
• 8.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically Concerning Stem Cell Potential in MS
  • 8.3.1 On Stem Cell Media Coverage
  • 8.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
  • 8.3.3 On the Treatment of Neurological Disorders
  • 8.3.4 On Stem Cell Treatment of MS - Viability, Curative Power, Treatment Strategy and Results
  • 8.3.5 On the Timeframe for Marketable Stem Cell Treatment Options
• 8.4 Concluding Thoughts
  • 8.4.1 Concerning Symptom Management
  • 8.4.2 Concerning Current Treatments and Patient Sub-Groups
  • 8.4.3 Concerning Oral Drugs
  • 8.4.4 Concerning Stem Cell Treatment

9 Conclusions

• 9.1 The MS Market Will Achieve Continued Growth
• 9.2 Great Scope for an Oral MS Drug to Enter the Market
• 9.3 Major Players in the MS Market
• 9.4 Market Drivers
• 9.5 Market Restraints
• 9.6 MS Market - Overview

List of Tables

• Table 2.1 The Kurtzke Expanded Disability Scale
• Table 3.1 The Total Market for MS Drugs: Revenue ($m) Forecast, 2009-2024
• Table 3.2 Revenues ($m), 7-Year CAGR (%) and Market Share (%) for the Leading MS Drugs, 2007 & 2014
• Table 3.3 Top 5 MS Products Rank Comparison, 2007 and 2024
• Table 4.1 MS Drugs: Revenue ($m) Forecast in the Seven Major Markets, 2009-2024
• Table 4.2 The Leading MS Drugs in the US Market, 2007
• Table 4.3 The Leading MS Drugs in the German Market, 2007
• Table 4.4 The Leading MS Drugs in the French Market, 2007
• Table 4.5 The Leading MS Drugs in the Italian Market, 2007
• Table 4.6 The Leading MS Drugs in the Canadian Market, 2007
• Table 4.7 The Leading MS Drugs in the Spanish Market, 2007
• Table 4.8 The Leading MS Drugs in the UK Market, 2007
• Table 5.1 A SWOT Chart for the MS Market, 2009-2024
• Table 6.1 Top 5 Companies in the MS Market, 2007
• Table 7.1 MS Pipeline Drugs: Phase II and Beyond, 2008

List of Figures

• Figure 3.1 The Total MS Market: Revenue ($m) Forecast, 2009-2024
• Figure 3.2 The Leading MS Drugs: Market Revenue ($m) Forecast, 2009-2024
• Figure 3.3 Leading MS Drugs: Revenue ($m) by Sector, 2007
• Figure 3.4 Leading MS Drugs: Market Share (%), 2007
• Figure 3.5 Leading MS Drugs: Market Share (%), 2014
• Figure 3.6 Avonex Revenue ($m) Forecast 2009-2024
• Figure 3.7 Copaxone Revenue ($m) Forecast 2009-2024
• Figure 3.8 Rebif Revenue ($m) Forecast 2009-2024
• Figure 3.9 Betaferon Revenue ($m) Forecast 2009-2024
• Figure 3.10 Tysabri Revenue ($m) Forecast 2009-2024
• Figure 4.1 The US MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.2 The German MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.3 The French MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.4 The Italian MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.5 The Canadian MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.6 The Spanish MS Market Revenue ($m) Forecast, 2009-2024
• Figure 4.7 The UK MS Market Revenue ($m) Forecast, 2009-2024
• Figure 9.1 Total Revenues ($m) for MS Drugs, 2009-2024

Companies Mentioned in this Report

• Active Biotech
• Acorda Therapeutics
• Aegera Idera
• Allergan
• Antisense Therapeutics
• Apitope
• Argyll Biotechnologies
• Asphelia
• Bayer-Schering
• Bayhill Therapeutics
• Berlex Laboratories
• Biogen Idec
• BioMS
• BioPartners
• BTG
• Elan Pharmaceuticals
• Eli Lilly
• Fornix
• GemacBio
• Genentech
• GlaxoSmithKline
• GW Pharmaceuticals
• IMS
• Indevus
• InterMune
• Isis
• Manhattan
• Medarex
• MediciNova
• Merck KGaA
• Merck Serono
• Millennium
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Mylan
• Natco Pharmaceuticals
• Neuren
• Novartis
• Opexa
• Orchestra Therapeutics
• Otsuka Pharmaceuticals
• PDL BioPharma
• Pfizer
• ReceptoPharm
• Rentschler
• Roche
• Sanofi-Aventis
• Teva
• Transition
• UCB